Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of a 3-dose, 28-Day Regimen of PfSPZ Vaccine in Healthy, Malaria-Naïve, Adult Subjects to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI Conducted 14, 42 or 70 Days After Immunization

NCT04966871 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT04966871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of a 3-dose, 28-Day Regimen of PfSPZ Vaccine in Healthy, Malaria-Naïve, Adult Subjects to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI Conducted 14, 42 or 70 Days After Immunization
Lead sponsor
Sanaria Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2021
Completion date
June 21, 2022
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria